MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 20...(ng to supportthe manufacture of MOXATAG ...)

Process to Explore Strategic Alternatives Ongoing

In February 2008, MiddleBrook announced that it engaged Morgan Stanley as its strategic advisor in the Company's ongoing strategic evaluation process. MiddleBrook is evaluating a full range of available strategic alternatives intended to further enhance shareholder value.

Strategic alternatives the Company may pursue could include, but are not limited to, continued execution of the Company's operating plan, the sale of some or all of the Company's assets, partnering or other collaboration agreements, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed.

FINANCIAL DETAILS

-- Total revenue, resulting entirely from net Keflex product sales, was

$2.9 million in the fourth quarter of 2007, compared to revenue of $3.1

million in the prior quarter, and $1.2 million for the fourth quarter

of 2006. Revenue during the full year of 2007 was $10.5 million, up

from revenue of $4.8 million during the full year of 2006. Increased

product sales in 2007 were mainly attributable to the Company's Keflex

750 mg strength capsules which were launched during the second half of

2006.

-- Operating expenses. Research and development expenses, which primarily

consist of salaries, stock-based compensation, and related expenses for